Basic Information
Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)
Regulatory Information
EMEA/H/C/004025
January 14, 2016
November 19, 2015
21
March 26, 2025
Company Information
Ireland
Damastown Industrial Park Mulhuddart Dublin 15
VIATRIS PHARMA LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Overview Summary
Lopinavir/Ritonavir Viatris is used in combination with other medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Lopinavir/Ritonavir Viatris contains the active substances lopinavir and ritonavir. Lopinavir/Ritonavir Viatris is a ‘generic medicine’. This means that it contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Lopinavir/Ritonavir Viatris is Kaletra. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf).